.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,652,069

« Back to Dashboard

Claims for Patent: 7,652,069

Title:Polymorphs of suberoylanilide hydroxamic acid
Abstract:The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo. The present invention also provides a novel Form I polymorph of SAHA, characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well a unique crystalline structure.
Inventor(s): Miller; Thomas A. (Brookline, MA), Richon; Victoria M. (Wellesley, MA)
Assignee: Merck HDAC Research, LLC (Boston, MA)
Application Number:11/981,367
Patent Claims: 1. A pharmaceutical composition comprising an active ingredient consisting of suberoylanilide hydroxamic acid (SAHA) Form I characterized by an X-ray diffraction pattern including characteristic peaks at about 9.0, 9.4, 17.5, 19.4, 20.0, 24.0, 24.4, 24.8, 25.0, 28.0, and 43.3 degrees 2.theta., wherein the X-ray diffraction is measured with a Copper X-ray source; and further characterized by a Differential Scanning Calorimetry (DSC) thermogram having a single maximum value at about 164.4.+-.2.0, as measured by a Perkins Elmer DSC 6 Instrument, and a pharmaceutically acceptable carrier.

2. A pharmaceutical composition comprising an active ingredient consisting of suberoylanilide hydroxamic acid (SAHA) Form I characterized by an X-ray diffraction pattern including characteristic peaks at about 9.4, 17.5, 19.4, 20.0, 24.0, and 28.0 degrees 2.theta., wherein the X-ray diffraction is measured with a Copper X-ray source; and further characterized by a Differential Scanning Calorimetry (DSC) thermogram having a single maximum value at about 164.4.+-.2.0, as measured by a Perkins Elmer DSC 6 Instrument, and a pharmaceutically acceptable carrier.

3. A pharmaceutical composition comprising an active ingredient consisting of suberoylanilide hydroxamic acid (SAHA) Form I characterized by an X-ray diffraction pattern including characteristic peaks at about 9.4, 17.5, 19.4, 20.0, 24.0, and 28.0 degrees 2.theta., and lacking peaks at about 13.4-14.0 and 22.7-23.0 degrees 2.theta., wherein the X-ray diffraction is measured with a Copper X-ray source, and a pharmaceutically acceptable carrier.

4. The pharmaceutical composition according to claim 3, wherein the SAHA Form I is further characterized by a Differential Scanning Calorimetry (DSC) thermogram having a single maximum value at about 164.4.+-.2.0, as measured by a Perkins Elmer DSC 6 Instrument.

5. A pharmaceutical composition comprising an active ingredient consisting of a crystalline form of SAHA designated as Form I and a pharmaceutically acceptable carrier, wherein the SAHA Form I is characterized by an X-ray diffraction pattern including characteristic peaks at about 9.4, 17.5, 19.4, 20.0, 24.0, and 28.0 degrees 2.theta., wherein the X-ray diffraction is measured with a Copper X-ray source, obtainable by a method comprising the step of recrystallizing a crude preparation of SAHA from a mixture of methanol and water.

6. The pharmaceutical composition according to claim 5, wherein said mixture of methanol and water is a mixture of about 2:1 of methanol/water.

7. The pharmaceutical composition of claim 5, wherein the SAHA Form I is obtainable by a method comprising the steps of: a. reacting suberic acid with aniline to form suberanilic acid having the structure: ##STR00057## or a salt thereof b. reacting suberanilic acid with methanol to form methyl suberanilate having the structure: ##STR00058## c. reacting the methyl suberanilate with hydroxylamine hydrochloride to form a crude suberoylanilide hydroxamic acid in a reaction mixture; and d. recrystallizing said crude preparation of SAHA from a mixture of methanol and water.

8. The pharmaceutical composition according to claim 7, wherein said mixture of methanol and water is a mixture of about 2:1 of methanol/water.

9. The pharmaceutical composition according to claim 7, wherein step (c) further comprises the steps of: (1) adding sodium methoxide to the reaction mixture to obtain a clear solution; and (2) adding glacial acetic acid to the clear solution to form a precipitate comprising crude suberoylanilide hydroxamic acid.

10. A pharmaceutical composition comprising an active ingredient consisting of a crystalline form of SAHA designated as Form I and a pharmaceutically acceptable carrier, wherein the SAHA Form I is characterized by an X-ray diffraction pattern including characteristic peaks at about 9.4, 17.5, 19.4, 20.0, 24.0, and 28.0 degrees 2.theta., and lacking peaks at about 13.4-14.0 and 22.7-23.0 degrees 2.theta., wherein the X-ray diffraction is measured with a Copper X-ray source; obtainable by a method comprising the step of recrystallizing a crude preparation of SAHA from a mixture of methanol and water.

11. The pharmaceutical composition according to claim 10, wherein said mixture of methanol and water is a mixture of about 2:1 of methanol/water.

12. The pharmaceutical composition of claim 10, wherein the SAHA Form I is obtainable by a method comprising the steps of: a. reacting suberic acid with aniline to form suberanilic acid having the structure: ##STR00059## or a salt thereof b. reacting suberanilic acid with methanol to form methyl suberanilate having the structure: ##STR00060## c. reacting the methyl suberanilate with hydroxylamine hydrochloride to form a crude suberoylanilide hydroxamic acid in a reaction mixture; and d. recrystallizing said crude preparation of SAHA from a mixture of methanol and water.

13. The pharmaceutical composition according to claim 12, wherein said mixture of methanol and water is a mixture of about 2:1 of methanol/water.

14. The pharmaceutical composition according to claim 12, wherein step (c) further comprises the steps of: (1) adding sodium methoxide to the reaction mixture to obtain a clear solution; and (2) adding glacial acetic acid to the clear solution to form a precipitate comprising crude suberoylanilide hydroxamic acid.

15. A pharmaceutical composition comprising an active ingredient consisting of a crystalline form of SAHA designated as Form I and a pharmaceutically acceptable carrier, wherein the SAHA Form I is characterized by an X-ray diffraction pattern including characteristic peaks at about 9.0, 9.4, 17.5, 19.4, 20.0, 24.0, 24.4, 24.8, 25.0, 28.0, 43.3 degrees 2.theta., wherein the X-ray diffraction is measured with a Copper X-ray source; obtainable by a method comprising the steps of: a. reacting suberic acid with aniline to form suberanilic acid having the structure: ##STR00061## or a salt thereof b. reacting suberanilic acid with methanol to form methyl suberanilate having the structure: ##STR00062## c. reacting the methyl suberanilate with hydroxylamine hydrochloride to form a crude suberoylanilide hydroxamic acid in a reaction mixture; and d. recrystallizing said crude preparation of SAHA from a mixture of methanol and water.

16. The pharmaceutical composition according to claim 15, wherein said mixture of methanol and water is a mixture of about 2:1 of methanol/water.

17. The pharmaceutical composition according to claim 15, wherein step (c) further comprises the steps of: (1) adding sodium methoxide to the reaction mixture to obtain a clear solution; and (2) adding glacial acetic acid to the clear solution to form a precipitate comprising crude suberoylanilide hydroxamic acid.

18. A pharmaceutical composition comprising an active ingredient consisting of a crystalline form of SAHA designated as Form I and a pharmaceutically acceptable carrier, wherein the SAHA Form I is characterized by an X-ray diffraction pattern including characteristic peaks at about 9.0, 9.4, 17.5, 19.4, 20.0, 24.0, 24.4, 24.8, 25.0, 28.0, 43.3 degrees 2.theta., wherein the X-ray diffraction is measured with a Copper X-ray source; and further characterized by a Differential Scanning Calorimetry (DSC) thermogram having a single maximum value at about 164.4.+-.2.0, as measured by a Perkins Elmer DSC 6 Instrument; obtainable by a method comprising the steps of: a. reacting suberic acid with aniline to form suberanilic acid having the structure: ##STR00063## or a salt thereof b. reacting suberanilic acid with methanol to form methyl suberanilate having the structure: ##STR00064## c. reacting the methyl suberanilate with hydroxylamine hydrochloride to form a crude suberoylanilide hydroxamic acid in a reaction mixture; and d. recrystallizing said crude preparation of SAHA from a mixture of methanol and water.

19. The pharmaceutical composition according to claim 18, wherein said mixture of methanol and water is a mixture of about 2:1 of methanol/water.

20. The pharmaceutical composition according to claim 18, wherein step (c) further comprises the steps of: (1) adding sodium methoxide to the reaction mixture to obtain a clear solution; and (2) adding glacial acetic acid to the clear solution to form a precipitate comprising crude suberoylanilide hydroxamic acid.

21. The pharmaceutical composition of any one of claims 1, 2, 4, and 18, wherein the DSC measurement is performed by heating from 50.degree. C. at 10.degree. C. per minute to at least 30.degree. C. above the observed melting temperature.

22. The pharmaceutical composition of claim 21, wherein the DSC measurement is performed with Perkin Elmer standard aluminum DSC sample pans and covers, with a nitrogen gas purge rate at about 20 ml/min.

23. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is in solid dosage form for oral administration.

24. The pharmaceutical composition of claim 2, wherein the pharmaceutical composition is in solid dosage form for oral administration.

25. The pharmaceutical composition of claim 3, wherein the pharmaceutical composition is in solid dosage form for oral administration.

26. The pharmaceutical composition of claim 4, wherein the pharmaceutical composition is in solid dosage form for oral administration.

27. The pharmaceutical composition of claim 5, wherein the pharmaceutical composition is in solid dosage form for oral administration.

28. The pharmaceutical composition of claim 6, wherein the pharmaceutical composition is in solid dosage form for oral administration.

29. The pharmaceutical composition of claim 7, wherein the pharmaceutical composition is in solid dosage form for oral administration.

30. The pharmaceutical composition of claim 8, wherein the pharmaceutical composition is in solid dosage form for oral administration.

31. The pharmaceutical composition of claim 9, wherein the pharmaceutical composition is in solid dosage form for oral administration.

32. The pharmaceutical composition of claim 10, wherein the pharmaceutical composition is in solid dosage form for oral administration.

33. The pharmaceutical composition of claim 11, wherein the pharmaceutical composition is in solid dosage form for oral administration.

34. The pharmaceutical composition of claim 12, wherein the pharmaceutical composition is in solid dosage form for oral administration.

35. The pharmaceutical composition of claim 13, wherein the pharmaceutical composition is in solid dosage form for oral administration.

36. The pharmaceutical composition of claim 14, wherein the pharmaceutical composition is in solid dosage form for oral administration.

37. The pharmaceutical composition of claim 15, wherein the pharmaceutical composition is in solid dosage form for oral administration.

38. The pharmaceutical composition of claim 16, wherein the pharmaceutical composition is in solid dosage form for oral administration.

39. The pharmaceutical composition of claim 17, wherein the pharmaceutical composition is in solid dosage form for oral administration.

40. The pharmaceutical composition of claim 18, wherein the pharmaceutical composition is in solid dosage form for oral administration.

41. The pharmaceutical composition of claim 19, wherein the pharmaceutical composition is in solid dosage form for oral administration.

42. The pharmaceutical composition of claim 20, wherein the pharmaceutical composition is in solid dosage form for oral administration.

43. The pharmaceutical composition of claim 21, wherein the pharmaceutical composition is in solid dosage form for oral administration.

44. The pharmaceutical composition of claim 22, wherein the pharmaceutical composition is in solid dosage form for oral administration.

45. The pharmaceutical composition of claim 1 that comprises about 100 mg of the SAHA.

46. The pharmaceutical composition of claim 2 that comprises about 100 mg of the SAHA.

47. The pharmaceutical composition of claim 3 that comprises about 100 mg of the SAHA.

48. The pharmaceutical composition of claim 4 that comprises about 100 mg of the SAHA.

49. The pharmaceutical composition of claim 5 that comprises about 100 mg of the SAHA.

50. The pharmaceutical composition of claim 6 that comprises about 100 mg of the SAHA.

51. The pharmaceutical composition of claim 7 that comprises about 100 mg of the SAHA.

52. The pharmaceutical composition of claim 8 that comprises about 100 mg of the SAHA.

53. The pharmaceutical composition of claim 9 that comprises about 100 mg of the SAHA.

54. The pharmaceutical composition of claim 10 that comprises about 100 mg of the SAHA.

55. The pharmaceutical composition of claim 11 that comprises about 100 mg of the SAHA.

56. The pharmaceutical composition of claim 12 that comprises about 100 mg of the SAHA.

57. The pharmaceutical composition of claim 13 that comprises about 100 mg of the SAHA.

58. The pharmaceutical composition of claim 14 that comprises about 100 mg of the SAHA.

59. The pharmaceutical composition of claim 15 that comprises about 100 mg of the SAHA.

60. The pharmaceutical composition of claim 16 that comprises about 100 mg of the SAHA.

61. The pharmaceutical composition of claim 17 that comprises about 100 mg of the SAHA.

62. The pharmaceutical composition of claim 18 that comprises about 100 mg of the SAHA.

63. The pharmaceutical composition of claim 19 that comprises about 100 mg of the SAHA.

64. The pharmaceutical composition of claim 20 that comprises about 100 mg of the SAHA.

65. The pharmaceutical composition of claim 21 that comprises about 100 mg of the SAHA.

66. The pharmaceutical composition of claim 22 that comprises about 100 mg of the SAHA.

67. A pharmaceutical composition comprising an active ingredient consisting of a crystalline form of SAHA designated as Form I and a pharmaceutically acceptable carrier, wherein the SAHA Form I is characterized by an X-ray diffraction pattern including characteristic peaks at about 9.4, 17.5, 19.4, 20.0, 24.0, and 28.0 degrees 2.theta., wherein the X-ray diffraction is measured with a Copper X-ray source, obtainable by a method comprising the step of recrystallizing a crude preparation of SAHA from an organic solvent, or a mixture of an organic solvent and water, wherein the organic solvent is at least one of methanol, ethanol or isopropanol.

68. The pharmaceutical composition according to claim 67, wherein the method comprises the step of recrystallizing a crude preparation of SAHA from a mixture of 15-85% methanol, ethanol or isopropanol and about 1-15% water.

69. The pharmaceutical composition according to claim 67, wherein the method comprises the step of recrystallizing a crude preparation of SAHA from methanol, ethanol or isopropanol.

70. The pharmaceutical composition of claim 67, wherein the crude preparation of SAHA is obtainable by a method comprising the steps of: a. reacting suberic acid with aniline to form suberanilic acid having the structure: ##STR00065## or a salt thereof b. reacting suberanilic acid with methanol to form methyl suberanilate having the structure: ##STR00066## c. reacting the methyl suberanilate with hydroxylamine hydrochloride to form a crude suberoylanilide hydroxamic acid in a reaction mixture.

71. The pharmaceutical composition of claim 68, wherein the crude preparation of SAHA is obtainable by a method comprising the steps of: a. reacting suberic acid with aniline to form suberanilic acid having the structure: ##STR00067## or a salt thereof b. reacting suberanilic acid with methanol to form methyl suberanilate having the structure: ##STR00068## c. reacting the methyl suberanilate with hydroxylamine hydrochloride to form a crude suberoylanilide hydroxamic acid in a reaction mixture.

72. The pharmaceutical composition of claim 69, wherein the crude preparation of SAHA is obtainable by a method comprising the steps of: a. reacting suberic acid with aniline to form suberanilic acid having the structure: ##STR00069## or a salt thereof b. reacting suberanilic acid with methanol to form methyl suberanilate having the structure: ##STR00070## c. reacting the methyl suberanilate with hydroxylamine hydrochloride to form a crude suberoylanilide hydroxamic acid in a reaction mixture.

73. The pharmaceutical composition according to claim 70, wherein step (c) further comprises the steps of: (1) adding sodium methoxide to the reaction mixture to obtain a clear solution; and (2) adding glacial acetic acid to the clear solution to form a precipitate comprising crude suberoylanilide hydroxamic acid.

74. The pharmaceutical composition according to claim 71, wherein step (c) further comprises the steps of: (1) adding sodium methoxide to the reaction mixture to obtain a clear solution; and (2) adding glacial acetic acid to the clear solution to form a precipitate comprising crude suberoylanilide hydroxamic acid.

75. The pharmaceutical composition according to claim 72, wherein step (c) further comprises the steps of: (1) adding sodium methoxide to the reaction mixture to obtain a clear solution; and (2) adding glacial acetic acid to the clear solution to form a precipitate comprising crude suberoylanilide hydroxamic acid.

76. The pharmaceutical composition of claim 67, wherein the pharmaceutical composition is in solid dosage form for oral administration.

77. The pharmaceutical composition of claim 68, wherein the pharmaceutical composition is in solid dosage form for oral administration.

78. The pharmaceutical composition of claim 69, wherein the pharmaceutical composition is in solid dosage form for oral administration.

79. The pharmaceutical composition of claim 70, wherein the pharmaceutical composition is in solid dosage form for oral administration.

80. The pharmaceutical composition of claim 71, wherein the pharmaceutical composition is in solid dosage form for oral administration.

81. The pharmaceutical composition of claim 72, wherein the pharmaceutical composition is in solid dosage form for oral administration.

82. The pharmaceutical composition of claim 73, wherein the pharmaceutical composition is in solid dosage form for oral administration.

83. The pharmaceutical composition of claim 74, wherein the pharmaceutical composition is in solid dosage form for oral administration.

84. The pharmaceutical composition of claim 75, wherein the pharmaceutical composition is in solid dosage form for oral administration.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc